Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

“The selected companies and individuals have helped advance the use and understanding of SAFE-BioPharma as a way to ensure trust in online identities and to apply legally-binding digital signatures to electronic documents,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. The board of directors of the non-profit consortium made the selections from nominations submitted from the biopharmaceutical, healthcare and information security sectors.

Astellas Pharma was selected for a SAFE-BioPharma virtual clinical study pilot project in Japan involving the Japan Medical Association Center for Clinical Trials and three general hospitals under Ibaraki Hospital Center of Hitachi. In the pilot, clinical trial contracts and IRB review reports were signed digitally by Astellas as a virtual sponsor and by medical professionals at the hospitals.

Steven Friedman, National Cancer Institute, and Cindy Cullen, Bristol-Myers Squibb, were selected for their participation in a pioneering use of interoperable digital identities by a small group of government and industry cancer researchers that demonstrates how clinical trial initiation can be accelerated while reducing costs.

Peter Alterman, Assistant CIO for EAuthentication, National Institutes of Health, was selected for playing a critical role (as chairman of the Federal PKI Policy Authority) in creating foundational tools for developing and promulgating use of interoperable digital identities by U.S. government employees and for ushering in the era of eSubmissions. The judges also cited Dr. Alterman’s leadership in laying the groundwork for conducting future paperless clinical trials

This is the first of what will become an annual nomination and selection process.

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs